▼ bearish
Impact
PhaseApproved
Time to marketAlready on the market (approved 2012, expanded label 2019)
IPE icosapent ethyl Updated Oct 25
What to watch
Watch the Q3 2026 earnings release (~Oct 27–Nov 4) for updates on US market share erosion, net pricing trends, and international volume growth via Recordati. Key to watch: whether branded US market share can stabilize above 45% and whether operating expense cuts continue to offset top-line pressure. The EMT2 oncology results, while scientifically interesting, are not a near-term commercial catalyst and do not change the fundamental generic-overhang thesis.
Bull case
- Vascepa's US branded market share actually grew to 48% in Q2 2026 (from 43% a year earlier) despite generic pressure, with branded prescriptions up 14% YoY
- International expansion via the Recordati partnership (59 countries, Europe-focused) drove 69% YoY European volume growth in Q2 2026, creating a diversified revenue base
- Operating expenses declined 59% YoY in Q2 2026; company generated positive cash flow and improved its cash position
Bear case
- The Supreme Court unanimously ruled against Amarin in Hikma v. Amarin (June 2026), removing a key legal barrier that had limited generic competition, Hikma and Dr Reddy's can now aggressively market their generics
- US Vascepa product revenue declined to $32.2M in Q2 2026 (from $36.5M in Q2 2025), with net pricing under continuing pressure from generic entrants
- Total Q2 2026 net revenue fell 42% YoY to $42.2M, partly due to the absence of the prior-year $25M Recordati upfront payment, but underlying product revenue was also down